Brian Poma
Get their honest, personalized take on your startup.
Sign in to pitch Brian →At a glance
- Full Name
- Brian David Poma
- Title
- Chief Executive Officer; Partner and Portfolio Manager
- Firm
- Neumeier Poma Investment Counsel LLC
- Firm Type
- SEC-registered investment adviser / public-equities investment manager
- Investment Stage
- Public small-cap value equities
- Target Company Profile
- Undervalued, misunderstood, or undiscovered small-cap public companies, often with defensible competitive advantages and strong fundamentals.
- Sector Focus
- Health care, technology, and energy are listed as Brian Poma’s primary research responsibilities; the firm invests across the small-cap value universe.
- Geographic Focus
- U.S. public equities
- Location
- Carmel / Carmel Highlands, California
Background
Brian David Poma is Chief Executive Officer and a member of Neumeier Poma Investment Counsel LLC, an investment adviser based in Carmel, California. SEC filings list him as the person signing the firm’s Form 13F reports on behalf of the manager, with the title Chief Executive Officer. Private Fund Data, citing Form ADV, lists him as a member and chief executive officer with a 50%–75% beneficial ownership band and a control-person status since 2008.
Poma joined Neumeier Investment Counsel in January 2000 as the firm’s trader. According to The Wall Street Transcript, he learned the firm’s value-investing approach there, became a senior analyst in 2003, received the CFA designation in 2005, was promoted to portfolio manager in 2006, and became an equity partner in July 2008. His research coverage has included health care, technology, and energy.
He graduated from UCLA in 1999 with a B.A. in economics. His LinkedIn profile also lists UCLA from 1995 to 1999 and a CFA Institute charter issued in September 2005.
Public sources do not verify the stub’s claim that he is primarily an angel or seed investor. The verified record points to a public-equities small-cap value manager, not a conventional startup angel profile.
Investment Thesis & Focus
- Neumeier Poma’s public-equities strategy is described as capitalizing on “undervalued, misunderstood, and undiscovered companies” in the small-cap value universe.
- The firm uses bottom-up fundamental research and may run concentrated portfolios based on its analysis of individual companies and sectors.
- In a 2013 Wall Street Transcript excerpt, Poma said the firm looks for companies with “some sort of edge over their competition that is highly defensible.”
- Poma’s Questcor example emphasized debt-free balance sheets, cash per share, double-digit return on equity, high profit margins, rapid sales growth, and barriers to generic competition.
- The firm’s 13F filings show a public-stock portfolio rather than private-company seed deals; the Q1 2026 filing reported 41 holdings with a total reported Form 13F value of about $1.213 billion.
Notable Investments
- Questcor Pharmaceuticals: Biopharmaceutical company focused on central nervous system and autoimmune disorders; Poma said the firm first identified it in early 2010, and by the 2013 interview the stock had quintupled from the firm’s initial purchase.
- Adtalem Global Education: Public education-services company; listed by Fintool as a top Q2 2025 Neumeier Poma holding at about $49.4 million.
- Celestica: Electronics manufacturing and supply-chain company; listed as a top Q2 2025 holding at about $47.8 million.
- OSI Systems: Security, inspection, and healthcare technology company; listed as a top Q2 2025 holding at about $44.4 million.
- ExlService Holdings: Analytics and operations-management services company; listed as a top Q2 2025 holding at about $43.8 million.
- Limbach Holdings: Building systems and specialty contracting company; listed as a top Q2 2025 holding at about $40.4 million.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.